Comparison of the hyper-cvad with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico

Authors

  • Christian Omar Ramos-Peñafiel Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano
  • Álvaro Cabrera-García Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano
  • Etta Rozen-Fuller Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano
  • Guadalupe González-León Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano
  • Carolina Balderas Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano
  • Juan Julio Kassack-Ipiña Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano
  • Humberto Castellanos-Sinco Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano
  • Carlos Martínez-Murillo Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano
  • Efreen Montaño-Figueroa Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano
  • Adolfo Martínez-Tovar Hospital General de México. Distrito Federal, México Doctor en Genética y Biología Molecular
  • Irma Olarte-Carrillo Hospital General de México. Distrito Federal, México doctor en Ciencias Biológicas y de la Salud
  • Adrián Santoyo-Sánchez Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México. estudiante de Medicina.
  • Juan Collazo-Jaloma Hospital General de México. Distrito Federal, México Facultad de Medicina, Universidad Nacional Autónoma de México. Distrito Federal, México Médico cirujano

DOI:

https://doi.org/10.17843/rpmesp.2014.313.91

Keywords:

Leukemia, lymphoblastic, Antineoplastic combined chemotherapy protocols, Adult

Abstract

In order to assess the mortality and toxicity of the Hyper-CVAD protocol used as first-line treatment of acute lymphoblastic leukemia, a retrospective cohort study was performed in patients less than 40 years of age from March to September 2011 treated with Hyper-CVAD regimen. Mortality and toxicity was compared with the results of patients treated with the institutional HGMLAL07 regimen between 2009-2012. 18 patients were included; the median age was 26 years old. Complete remissions (67.7% versus 81.9%) as well as one-year (40% versus 62%) and 2 year survival rates (18% versus 34%) were lower with the Hyper-CVAD regimen. By selecting only patients younger than 35 years, the effectiveness of Hyper-CVAD was also lower. In our experience and because of its high cost and toxicity, the Hyper-CVAD regimen should be limited to patients with relapsed or refractory leukemia.

Downloads

Download data is not yet available.

Published

2014-09-25

Issue

Section

Research Articles

How to Cite

1.
Ramos-Peñafiel CO, Cabrera-García Álvaro, Rozen-Fuller E, González-León G, Balderas C, Kassack-Ipiña JJ, et al. Comparison of the hyper-cvad with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico. Rev Peru Med Exp Salud Publica [Internet]. 2014 Sep. 25 [cited 2024 Dec. 10];31(3). Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/91